3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
2
Status
Withdrawn
2
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Other hematologic neoplasm
2
Conditions
Leukemia, Myeloid, Acute
2
Invasive Pulmonary Aspergillosis
1
Interventions
Azacitidine
142
Cytarabine
109
venetoclax
94
fludarabine
35
Daunorubicin
34
Decitabine
32
Idarubicin
26
gilteritinib
24
Cyclophosphamide
21
quizartinib
15
midostaurin
15
Mitoxantrone
14
Etoposide
14
Granulocyte Colony-Stimulating Factor
12
Gemtuzumab
11
CPX-351
11
decitabine and cedazuridine drug combination
10
Drug Therapy
10
cc-486
9
Filgrastim
9
Clofarabine
9
ivosidenib
8
Injections
8
Dexamethasone
8
pevonedistat
7
fludarabine phosphate
7
AP 1903 reagent
7
posaconazole
6
magrolimab
6
glasdegib
6
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
INDUSTRY
×
Leukemia, Myeloid, Acute
×
olorofim
×
Clear all
NCT02856178
2018-02-15
SAFEGUARD
F2G Biotech GmbH
Phase 1/2
Withdrawn
NCT03036046
2018-02-15
SAFEGUARDFP
F2G Biotech GmbH
Phase 1/2
Withdrawn